Concurrent gemcitabine and radiotherapy for the treatment of muscle-invasive bladder cancer: A pooled individual data analysis of eight phase I–II trials

Caffo, Orazio; Thompson, Catherine; Santis, Maria De; Kragelj, Borut; Hamstra, Daniel A.; Azria, D.; Fellin, Gianni; Pappagallo, Giovanni; Galligioni, Enzo; Choudhury, Ananya

doi:10.1016/j.radonc.2016.09.006

Cited by 42 publications

(15 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In BC2001, a total of 360 patients were randomized to mitomycin C and infusional 5‐fluorouracil with RT versus RT alone, with patients receiving chemoradiotherapy having a better absolute locoregional recurrence‐free survival rate of 13%. Meta‐analyses of low‐dose gemcitabine with RT and the pooled analyses of the Radiation Therapy Oncology Group studies confirm that bladder preservation with other protocols is effective and deliverable with acceptable toxicity …”

Section: Introductionmentioning

confidence: 88%

Bladder cancer and the National Cancer Data Base: New insight or misinformation?

Choudhury

Hoskin

2018

Cancer

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 88%

Bladder cancer and the National Cancer Data Base: New insight or misinformation?

Choudhury

Hoskin

2018

Cancer

Self Cite

View full text Add to dashboard Cite

show abstract

“…The use of concurrent 5-fluorouacil plus mitomycin C (5-fluorouracil administered as a continuous infusion at 500 mg/m 2 daily on days 1 to 5 and 16-20 of radiotherapy, mitomycin administered as an intravenous bolus dose of 12 mg/m 2 on day 1) is supported by a large randomized phase III trial [123]. Low dose gemcitabine [236][237][238][239] is another alternative especially in more frail patients. Comparative trials are needed to elucidate the optimal radiosensitizer in TMT.…”

Section: Trimodality Therapy (Tmt)mentioning

confidence: 99%

Current Management of Localized Muscle-Invasive Bladder Cancer: A Consensus Guideline from the Genitourinary Medical Oncologists of Canada

Jiang

North

Canil

et al. 2020

BLC

View full text Add to dashboard Cite

BACKGROUND: Despite recent advances in the management of muscle-invasive bladder cancer (MIBC), treatment outcomes remain suboptimal, and variability exists across current practice patterns. OBJECTIVE: To promote standardization of care for MIBC in Canada by developing a consensus guidelines using a multidisciplinary, evidence-based, patient-centered approach who specialize in bladder cancer. METHODS: A comprehensive literature search of PubMed, Medline, and Embase was performed; and most recent guidelines from national and international organizations were reviewed. Recommendations were made based on best available evidence, and strength of recommendations were graded based on quality of the evidence. RESULTS: Overall, 17 recommendations were made covering a broad range of topics including pathology review, staging investigations, systemic therapy, local definitive therapy and surveillance. Of these, 10 (59% ) were level 1 or 2, 7 (41% ) were level 3 or 4 recommendations. There were 2 recommendations which did not reach full consensus, and were based on majority opinion. This guideline also provides guidance for the management of cisplatin-ineligible patients, variant histologies, and bladder-sparing trimodality therapy. Potential biomarkers, ongoing clinical trials, and future directions are highlighted. CONCLUSIONS: This guideline embodies the collaborative expertise from all disciplines involved, and provides guidance to further optimize and standardize the management of MIBC.

show abstract

“…Die Rate von akuten Komplikationen während TMT ist relativ hoch (insgesamt bis zu 62.1 % für alle Komplikationsgrade), während die Langzeittoxizität insbesondere für höhergradige Komplikationen deutlich niedriger ist (G3 -5 Komplikationen nur in 3.1 -7 %) [62,68]. Die häufigsten Langzeitkomplikationen sind Urge-Symptomatik, Hämaturie oder gastrointestinale Beschwerden (Sigma-Obstruktion, Proktitis) [68].…”

Section: Tmt -Komplikationenunclassified

Nur die Chirurgie? Multimodalkonzepte mit kurativer Intention für das Urothelkarzinom der Harnblase

2020

View full text Add to dashboard Cite

ZusammenfassungDie radikale Zystektomie ist der Goldstandard zur Behandlung des muskelinvasiven Urothelkarzinoms. Insbesondere bei Patienten mit fortgeschrittenen Tumoren spielen multimodale, neoadjuvante oder adjuvante Therapiekonzepte eine zunehmend wichtige Rolle für die optimale Patientenversorgung. Zudem sind bei älteren und komorbideren Patienten, die unfit für eine radikale Zystektomie sind, alternative Therapiekonzepte erforderlich. Dieser Artikel fasst die aktuelle Literatur multimodaler Therapien im neoadjuvanten und adjuvanten Setting zusammen und beleuchtet Alternativen zur radikalen Zystektomie mit kurativem Therapieansatz. Ebenfalls werden erste Erkenntnisse über den Einsatz neuer, vielversprechender Therapieoptionen wie der Immuncheckpoint-Blockade im multimodalen Therapieansatz zusammengefasst.

show abstract

Concurrent gemcitabine and radiotherapy for the treatment of muscle-invasive bladder cancer: A pooled individual data analysis of eight phase I–II trials

Cited by 42 publications

References 26 publications

Bladder cancer and the National Cancer Data Base: New insight or misinformation?

Bladder cancer and the National Cancer Data Base: New insight or misinformation?

Current Management of Localized Muscle-Invasive Bladder Cancer: A Consensus Guideline from the Genitourinary Medical Oncologists of Canada

Nur die Chirurgie? Multimodalkonzepte mit kurativer Intention für das Urothelkarzinom der Harnblase

Contact Info

Product

Resources

About